Viking Therapeutics (NasdaqCM:VKTX) has experienced an 11% monthly decline in its stock price, a notable movement amid its recent announcements and a wider market downturn. The company completed the ...

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply of ...

Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine targeting a chronic blood disorder.

An aerial sketch of CordenPharma’s future peptide manufacturing facility in Muttenz, Switzerland. Image: CordenPharma. As part of its growth initiatives, CordenPharma has finalized plans to establish ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about VKTX stock here.

Shares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad multi-year manufacturing agreement with CordenPharma for both the oral ...

Viking Therapeutics jumped by 11.43 percent on Wednesday to end at $29.55 each as investor sentiment was fueled by news that it partnered with CordenPharma for the production of its weight loss ...

Viking Therapeutics, Inc. (Viking), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that it has signed a broad ...

Yesterday, Viking signed a "broad manufacturing agreement" with Germany's CordenPharma to produce for it a "multi-ton annual ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking Therapeutics ( VKTX 2.08 ...